FDA approves Rybrevant for advanced lung cancer
The FDA approved the drug amivantamab-vmjw in combination with standard chemotherapy for the treatment of certain adults with non-small cell lung cancer, according to a press release by Johnson & Johnson. The indication applies to adults with locally advanced or metastatic…